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Insects are the pre-eminent form of
metazoan life on land, with as many as
1018 individuals alive at any one instant
and over three-quarters of a million
species described. Although it is estimated
that there are as many as 14,000 species
that are blood feeders [1], only three to
400 species regularly attract our attention
[2]. Some of these are of immense
importance to us, as vector-borne diseases
still form a huge burden on both the
human population (Table 1) and our
domesticated animals.
Much progress has been achieved in the
control of some of these vector-borne
diseases by targeting the vector. The
following are two good examples. First,
insecticide-treated mosquito nets (ITNs)
have had a major impact in the control of
malaria, even in some of the most difficult
control settings. The evidence from large-
scale assessments shows that households
possessing ITNs show a 20% reduction
in prevalence of Plasmodium falciparum
infection in children under 5 and a 23%
reduction in all-cause child mortality,
findings that were consistent across a
range of transmission settings [3]. Second,
the Southern Cone Initiative has used
indoor residual spraying against the do-
mesticated triatomine vectors of Chagas
disease to immense effect [4]. As a result,
the overall distribution of Triatoma infestans
in the Southern Cone region has been
reduced from well over 6 million km2
(1990 estimates) to around 750,000 km2
mainly in the Chaco of northeast Argen-
tina and Bolivia, while Rhodnius prolixus has
been almost entirely eliminated from
Central America, with all countries there
now certified by the World Health Orga-
nization (WHO) and Pan American
Health Organization (PAHO) as free of
transmission due to this vector.
However, the emergence and spread of
insecticide resistance [5] represents a
challenge to these successes and to other
vector control activities, the vast majority
of which depend in one way or another on
the use of insecticides. The need for new
insecticides (or novel means to use those
we already have) and for other non-
insecticidal means of vector control is
quite clear. A good example of our need
for new means of controlling insects is seen
in dengue. Without a vaccine or drugs,
disease control efforts are centred on
control of the vector. But, because of the
life histories of the vectors involved, the
methods we currently have are inadequate
[6].
One non-insecticidal method of vector
control, which incidentally shows much
promise for dengue control, is the use of
genetically modified (GM) insects. Serious
discussion of whether GM insects could be
used in control began as soon as transgenic
insects were first produced in the 1980s
[7], and a range of means by which this
could be achieved have been put forward
[8]. The first generation of GM insects,
designed to suppress rather than replace
vector populations, is now being pro-
duced. For example, the OX3604C strain
of Aedes aegypti is designed for the control of
this dengue vector [9]. Field release of GM
insects is under way [10,11], as described
by Reeves and colleagues in this issue [12].
GM insects may provide great promise for
new means of controlling diseases with a
devastating impact on people’s lives. If so,
then public acceptance is likely to be a key
issue in their implementation.
It seems possible that GM insect release
may prove an emotive issue. While not a
GM control campaign, Reeves et al. [12]
point to the decade-long WHO-led sterile
insect technique (SIT) programs in India
that finished in a chaotic way following ill-
informed but highly damaging reporting
in the Indian press [13,14]. Similarly, the
problems surrounding the use of GM
crops in Europe and the issues surround-
ing the polio vaccination campaign in
northern Nigeria [15] provide evidence of
the importance of carrying public opinion
if potentially beneficial technologies are to
be accepted. Part of the process of carrying
public opinion is to ensure that adequate
oversight of technologies is in place and
that the public is fully informed in an
appropriate manner [15]. It is clear that
research on GM vector insects has reached
a stage where we can expect many field
releases to take place in the near future.
However, despite efforts by the European
Food Safety Authority (EFSA), the Con-
vention on Biological Diversity (CBD) Ad
Hoc Technical Expert Group (AHTEG),
and others, it is not clear that the
regulatory processes required to oversee
these releases are firmly in place, a view
shared by others [16]. Although it is not a
GM release as neither of the organisms
involved have foreign genes inserted, the
recent Australian release of Ae. aegypti
transformed with Wolbachia (which reduces
the capacity of the mosquito to act as a
vector of dengue) [17] is an interesting
example of the state of regulation in this
general area. The authors state ‘‘Approval
for the release of Aedes aegypti containing
Wolbachia was provided by the Australian
Pesticides and Veterinary Medicines Au-
thority. Considering the novelty of the
proposed experiment it was not initially
clear how the open release of Wolbachia
infected mosquitoes should be regulated in
Australia. Finally after considerable con-
sultation the Australian Government
chose to regulate the release under existing
legislation as a Veterinary Chemical
product’’.
In addition to national regulation,
which is likely to be most easily organized,
Mumford [18] makes the point that at
least some GM insect releases may require
regional or international regulation be-
cause of the risk of widespread dispersal
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posed by the organisms. Obtaining re-
gional or international agreements will of
course add to the difficulty of developing
suitable regulatory processes. If releases of
GM insects are not to prove such a highly
contentious issue that it interferes with
testing and implementation, then the
subject requires an open and full debate
in the public arena and for regulatory
bodies to move rapidly to have effective
and transparent oversight in place.
Consequently, we are publishing the
Viewpoint article and two related Ex-
pert Commentaries in this issue with the
hope that they will help to open the
debate more fully on the issues sur-
rounding the regulation of GM vector
releases. We have also highlighted some
of the articles previously published in
PLoS journals in the Genetically Mod-
ified Insect Collection (http://www.
ploscollections.org/GMInsect) for our
readers interested in these topics. The
international community has invested
heavily in the development of a strong
vector biology community and also has
promoted the development of GM insect
technologies to control diseases devas-
tating animals and plants alike. Our
view is that healthy discussion in a
public forum can help to ensure the best
possible chance that the return on our
investment will be high.
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Table 1. Vector-borne disease still forms a huge burden on humankind.
Prevalence At Risk DALYs Major Vectors
Malaria 247 M 3.3 B 39 M Anopheline mosquitoes
Leishmaniasis 12 M 350 M 2 M Phlebotomine sandflies
Dengue 50 M 2.5 B 616 K Culicine mosquitoes
Lymphatic filariasis 120 M 1.3 B 5.8 M Mosquitoes
Sleeping sickness 30 K 70 M 1.5 M Tsetse flies
Chagas disease 10 M 25 M 667 K Triatomine bugs
An indication of the importance of some of the vector-borne diseases afflicting man can be seen from these WHO-derived estimates (http://www.who.int/mediacentre/
factsheets/en/, accessed 3 October 2011; DALYs [19]).
B, billion; K, thousand; M, million.
doi:10.1371/journal.pntd.0001495.t001
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